BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/30/2025 7:07:09 AM | Browse: 11 | Download: 50
 |
Received |
|
2025-05-07 02:44 |
|
Peer-Review Started |
|
2025-05-07 02:44 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-05-17 07:57 |
|
Revised |
|
2025-05-31 13:34 |
|
Second Decision |
|
2025-09-08 02:46 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-09-08 09:09 |
|
Articles in Press |
|
2025-09-08 09:09 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-10-27 02:05 |
|
Publish the Manuscript Online |
|
2025-10-30 07:07 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Kirsten rat sarcoma G12C inhibitor treatment for a patient with relapsed metastatic lung adenocarcinoma: A case report
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Lei Gan, Jiao-Feng Shen, Meng-Xian Yao, Zhi-Gang Chen and Zhi-Xiang Zhuang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Sciences Foundation of China |
81803553 |
|
| Corresponding Author |
Lei Gan, PhD, Department of Oncology, The Second Affiliated Hospital of Soochow University, No. 1055 Sanxiang Road, Gusu District, Suzhou 215004, Jiangsu Province, China. ganlei19870810@163.com |
| Key Words |
Non-small cell lung cancer; Kirsten rat sarcoma G12C; Targeted therapy; Gene mutation; Case report |
| Core Tip |
Non-small cell lung cancer represents 85% of all pulmonary malignancies globally. Kirsten rat sarcoma viral oncogene homolog (KRAS) is among the most common mutations observed in malignant tumors, with roughly 13% of pulmonary adenocarcinomas carrying the KRAS at glycine 12 to cysteine (G12C) mutation. In this case, the initial therapeutic strategies for KRAS G12C-mutant lung adenocarcinomas were similar to those for driver mutation-negative non-small cell lung cancer. Following relapse, with KRAS G12C inhibitor administration, the patient’s post-relapse progression-free survival reached 17 months. Subsequently, the patient’s disease progressed, necessitating renewed treatment with radiotherapy, chemotherapy, and targeted therapy. |
| Publish Date |
2025-10-30 07:07 |
| Citation |
<p>Gan L, Shen JF, Yao MX, Chen ZG, Zhuang ZX. Kirsten rat sarcoma G12C inhibitor treatment for a patient with relapsed metastatic lung adenocarcinoma: A case report. <i>World J Clin Cases</i> 2025; 13(31): 108942</p> |
| URL |
https://www.wjgnet.com/2307-8960/full/v13/i31/108942.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v13.i31.108942 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
